DEAR FELLOW SHAREHOLDER,
In the five short years since Knight Therapeutics was founded, we’ve come a long way. We’ve generated an impressive $219 million of net income, raised hundreds of millions of dollars at increasing valuations, made smart acquisitions, and have in-licensed a promising pipeline of innovative products.
Together, as shareholders, we’ve all benefited. The GUD news is we’re just getting started.
The bad news is the future we all believe is possible is now at risk.
Mr. Meir Jakobsohn, a director and shareholder of Knight, has nominated a slate of six directors selected by him alone to take control of our company. Essentially, Mr. Jakobsohn, a 7% shareholder of Knight, wants to take over the board to remove Jonathan Goodman, our founder and CEO, from the company and to gain access to Knight’s cash reserves.
Why? Because he needs to prop up Medison, his own private company in Israel, which has made less and less money each year since our 2015 investment.
That is why your vote at our upcoming 2019 Annual General Meeting (the “Meeting”) on May 7, 2019 is important.
You have a clear choice:
A proven board, aligned with shareholders, that is executing on a disciplined strategy for profitable growth;
A board led by a self-interested director beholden to his own private company, with a questionable track record, no experience, and a risky agenda.
We believe that the current strategy is the right one and that we should be relentless in properly executing. We also believe that the current directors who are aligned with Knight’s shareholders are the right ones. If the board’s recommendation to elect Nancy Harrison and Michael Tremblay are adopted, over 70% of the board will be composed of directors which have been appointed over the last four years. This is a pace of refreshment that is appropriate to a board of our size.
Shareholders are encouraged to vote their BLUE Proxy of Voting Instruction Form ahead of the voting deadline on Friday, May 3, 2019 at 5:00 p.m. (EST).
Shareholders with questions regarding voting the BLUE Proxy or VIF should contact Knight’s strategic shareholder advisor and proxy solicitation agent, Kingsdale Advisors, who can be reached by toll-free telephone in North America at 1-888-518-1552, by collect call outside North America at 416-867-2272, or by email at email@example.com.
James C. Gale, Chairman
Jonathan Ross Goodman, Director
Robert N. Lande